Skip to content

Author

H. Kim

We have 2 of 51 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Initial Enfortumab Vedotin Dose Reduction and Outcomes in Pretreated Advanced Urothelial Carcinoma.

Importance Initial enfortumab vedotin (EV) dose selection is increasingly relevant in advanced urothelial carcinoma (UC). Reduced starting doses may be selected for some patients, but their associations with clinical outcomes and tolerability remain uncertain. Objective To evaluate the association of physician-select...

In-Ho Kim, Chang Gon Kim, Jungmin Jo et al. · 0 citations
Open access Oct 2026

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma

The aim is to provide guidance for the optimisation and harmonisation of the management of patients with RCC across the different countries of Asia, drawing on the evidence provided by both Western and Asian trials.

R. Kanesvaran, V. Gruenwald, A. Wong et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.